| Market Capitalization (Millions $) |
813 |
| Shares
Outstanding (Millions) |
99 |
| Employees |
102 |
| Revenues (TTM) (Millions $) |
50 |
| Net Income (TTM) (Millions $) |
-194 |
| Cash Flow (TTM) (Millions $) |
48 |
| Capital Exp. (TTM) (Millions $) |
10 |
Business Description
Verastem Inc is a biopharmaceutical company that specializes in discovering and developing small molecule drugs to treat cancer. The company is headquartered in Needham, Massachusetts, USA and was founded in 2010. Verastem Inc's focus is on developing medicines that target cancer stem cells, which are thought to be the root cause of tumor growth, recurrence, and metastasis.
The company's lead drug candidate is duvelisib, which is a dual inhibitor of PI3K-delta and PI3K-gamma. These are two enzymes that play a role in cell growth, differentiation, and survival. Duvelisib has been shown to have promising results in clinical trials for the treatment of blood cancers, such as chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and peripheral T-cell lymphoma (PTCL). The drug has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of relapsed/refractory PTCL and FL.
Apart from duvelisib, Verastem Inc has a pipeline of drug candidates that target cancer stem cells. These include VS-6766, which is a compound that inhibits both MEK and RAF kinases, and VS-6063, which is a focal adhesion kinase (FAK) inhibitor. These drugs are being developed for the treatment of solid tumors, such as ovarian, pancreatic, and lung cancers.
Verastem Inc has collaborations with pharmaceutical companies, academic institutions, and government agencies to advance its drug development programs. The company has a partnership with Yakult Honsha Co., Ltd. for the development and commercialization of duvelisib in Japan. It has also received funding from the National Cancer Institute (NCI) for clinical trials of its drug candidates.
In terms of its financial performance, Verastem Inc reported a net loss of $83 million in 2020. The company has a market capitalization of around $300 million and a share price of around $50 as of August 202 The company has raised over $500 million in funding from investors, including private equity firms, venture capitalists, and institutional investors.
In conclusion, Verastem Inc is a biopharmaceutical company that is focused on developing drugs to target cancer stem cells. Its lead drug candidate, duvelisib, has shown promise in clinical trials for the treatment of certain types of blood cancers. The company has a pipeline of drug candidates for the treatment of solid tumors and collaborations with pharmaceutical companies and research organizations. Despite posting losses in recent years, Verastem Inc remains committed to advancing its research and development efforts to bring innovative treatments to patients with cancer.
Company Address: 117 Kendrick Street, Suite 500 Needham 2494 MA
Company Phone Number: 292-4200 Stock Exchange / Ticker: NASDAQ VSTM
|
0.36% 
100 %